Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17824313 | 0.81 | MMP2 (0.54) | LMNAMMP2ALDH1A1L3MBTL1MEN1 | |
| SCHEMBL2607531 | 0.78 | MEN1 (0.62) | LMNAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL28571369 | 0.77 | BCHE (0.75) | — | |
| SCHEMBL15606690 | 0.76 | LMNA (0.64) | LMNASMN1; SMN2 | |
| SCHEMBL4288066 | 0.73 | KDM4E (0.65) | LMNAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL16626976 | 0.73 | KDM4E (0.58) | LMNAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL10387167 | 0.73 | — | — | |
| SCHEMBL15685947 | 0.72 | NPSR1 (0.69) | LMNAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL8268180 | 0.71 | KDM4E (0.67) | LMNAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL2610181 | 0.71 | MEN1 (0.68) | LMNAALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362184-A1 | PRO-SURVIVAL COMPOUNDS | HERIOT-WATT UNIVERSITY (GB) | 2017-12-21 | — | — | US | disclosed |
| EP-3230275-A1 | PRO-SURVIVAL COMPOUNDS | University Court of The University of Glasgow (GB) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016092327-A1 | PRO-SURVIVAL COMPOUNDS | UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362184-A1 | PRO-SURVIVAL COMPOUNDS | MCL1, MKI67, MORF4L1 | LMNA 301/4885MMP2 1711/4885ALDH1A1 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.